Leuthold Group LLC Purchases 1,723 Shares of Humana Inc. $HUM

Leuthold Group LLC purchased a new position in shares of Humana Inc. (NYSE:HUM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,723 shares of the insurance provider’s stock, valued at approximately $657,000.

A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Humana during the second quarter worth $4,138,160,000. Pzena Investment Management LLC purchased a new stake in shares of Humana in the second quarter valued at $1,749,014,000. Assenagon Asset Management S.A. increased its stake in Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after purchasing an additional 1,249,272 shares during the last quarter. Legal & General Group Plc acquired a new position in Humana in the second quarter valued at $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new position in Humana in the second quarter valued at $314,922,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana’s raised 2026 adjusted EPS outlook—to at least $9.50 from at least $9.00—helped sustain optimism after third-quarter results beat expectations for a smaller loss and higher revenue. Its 93.7% insurance benefit ratio was also favorable to prior guidance. Why Is Humana Stock Trading Higher Tuesday?
• Positive Sentiment: Humana, Evolent and American Oncology Network introduced an oncology care model intended to eliminate prior-authorization requirements for participating cancer care. The change may reduce administrative burden, though its financial impact was not specified. New oncology model from Humana, Evolent and American Oncology Network
• Positive Sentiment: Analysts raised price targets following the results, adding support to the bullish outlook. Recent examples include Guggenheim at $521, Barclays at $587 and JPMorgan at $484, though JPMorgan maintained a neutral rating. Humana Analysts Raise Their Forecasts After Q3 Results
• Neutral Sentiment: Humana launched cash tender offers for eight series of senior notes, with an aggregate purchase cap of $1.5 billion. The move represents active debt management, but the announcement does not establish a direct earnings benefit. Humana Commences Offers to Purchase Certain Debt Securities

Wall Street Analyst Weigh In

A number of analysts have issued reports on HUM shares. HSBC lowered Humana to a “hold” rating in a research note on Thursday, July 30th. Citigroup began coverage on Humana in a report on Friday, October 9th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Humana in a research note on Thursday, July 30th. They set a “hold” rating for the company. Jefferies Financial Group reiterated a “buy” rating and set a $420.00 price objective on shares of Humana in a report on Friday. Finally, Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 target price on the stock in a research report on Wednesday, July 29th. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $469.57.

Humana Trading Up 3.4%

Shares of HUM opened at $437.69 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $52.56 billion, a P/E ratio of 42.58, a price-to-earnings-growth ratio of 2.46 and a beta of 0.65. The stock’s fifty day simple moving average is $405.76 and its 200 day simple moving average is $313.90. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $456.50.

Humana (NYSE:HUM) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. During the same quarter last year, the firm earned $3.24 earnings per share. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities research analysts forecast that Humana Inc. will post 9.57 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a $0.8850 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s payout ratio is currently 34.44%.

Humana Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.